In:
Journal of Surgical Oncology, Wiley, Vol. 116, No. 6 ( 2017-11), p. 706-715
Abstract:
The Caspase14 (CASP14) was reported that the low expression of CASP14 in ovarian cancer and colon cancer was associated with cancer progression, on the other hand, that the CASP14 expression in breast cancer was higher than that of non‐cancerous tissues. The purpose of this study is to determine the clinical significance of CASP14 in breast cancer. Methods We performed immunohistochemistry for CASP14, ER, PgR, HER2, Ki67, EGFR, CK5/6, CD44, CD24, ALDH1, claudins, and androgen receptor in 222 breast cancer patients including 55 TNBC cases, and evaluated the relationship of CASP14, above‐mentioned markers, and prognosis. Using public microarray database of breast cancer, the prognostic value of CASP14 was calculated. Results High CASP14 expression was significantly associated with TNBC subtype ( P = 0.015), nuclear grade ( P = 0.006), Ki67, EGFR ( P 〈 0.001, P = 0.016), ALDH1, CD44 and CD24 ( P 〈 0.001, P 〈 0.001, P = 0.001) in 222 breast cancer cases, and the high expression of claudin1 ( P = 0.017), and androgen receptor ( P = 0.002) in TNBC cases was related to the high CASP14. According to the public database, survival in the high CASP14 breast cancer patients was shorter than low CASP14 patients. Conclusions High CASP14 expression is a marker of breast cancer aggressiveness in association with proliferation, TNBC phenotype, and cancer stemness.
Type of Medium:
Online Resource
ISSN:
0022-4790
,
1096-9098
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
1475314-5
Permalink